Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

Abstract

This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.